Table 4 Summary of adverse events and outcomes in QD and ADS groups
QD (n = 32) | ADS (n = 30) | |||
|---|---|---|---|---|
All events | Therapy-related events | All events | Therapy-related events | |
No. of adverse events | 5(15.6%) | 4(12.5%) | 7(23.3%) | 4(13.3%) |
Serious adverse events | 0 | 0 | 0 | 0 |
Adverse events | ||||
Liver dysfunction | 0 | 2(6.2%) | 1(3.3%) | 1(3.3%) |
Epigastric pain/abdominal pain | 0 | 2(6.2%) | 1(3.3%) | 1(3.3%) |
Leukopenia | 1(3.1%) | 0 | 0 | 1(3.3%) |
Elevated amylase | 0 | 0 | 1(3.3%) | 1(3.3%) |